![Gerald Chan](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Gerald Chan
Director/Board Member at Cognito Therapeutics, Inc.
Profile
Gerald Chan is currently a Director at Cognito Therapeutics, Inc. He was previously a Director at Stavvy, Inc.
Gerald Chan active positions
Companies | Position | Start |
---|---|---|
Cognito Therapeutics, Inc.
![]() Cognito Therapeutics, Inc. BiotechnologyHealth Technology Cognito Therapeutics, Inc. is a clinical-stage neurotechnology company based in Cambridge, MA. Cognito Therapeutics is developing disease-modifying therapeutic approaches to treat neurodegenerative disorders using its non-invasive neuromodulation platform. The company's lead therapy is currently in a pivotal study (HOPE) in Alzheimer's disease and has been awarded FDA breakthrough device designation. Cognito Therapeutics is advancing the field of neuromodulation to create novel therapeutics that improve the lives of patients living with neurodegenerative diseases. The company was founded by Li-Huei Tsai and Ed Boyden, and Brent A. Vaughan has been the CEO of the company since 2020. | Director/Board Member | - |
Former positions of Gerald Chan
Companies | Position | End |
---|---|---|
Stavvy, Inc.
![]() Stavvy, Inc. Packaged SoftwareTechnology Services Stavvy, Inc. provides information technology services. The company is headquartered in Newton, MA. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
Stavvy, Inc.
![]() Stavvy, Inc. Packaged SoftwareTechnology Services Stavvy, Inc. provides information technology services. The company is headquartered in Newton, MA. | Technology Services |
Cognito Therapeutics, Inc.
![]() Cognito Therapeutics, Inc. BiotechnologyHealth Technology Cognito Therapeutics, Inc. is a clinical-stage neurotechnology company based in Cambridge, MA. Cognito Therapeutics is developing disease-modifying therapeutic approaches to treat neurodegenerative disorders using its non-invasive neuromodulation platform. The company's lead therapy is currently in a pivotal study (HOPE) in Alzheimer's disease and has been awarded FDA breakthrough device designation. Cognito Therapeutics is advancing the field of neuromodulation to create novel therapeutics that improve the lives of patients living with neurodegenerative diseases. The company was founded by Li-Huei Tsai and Ed Boyden, and Brent A. Vaughan has been the CEO of the company since 2020. | Health Technology |
- Stock Market
- Insiders
- Gerald Chan